-			1010	-			_				
			/ 0.1	5	ATTY DOCKET NO.		APF	PLICA	TION N		
INFORMATION DISCLOSURE CITATION (Use several sheets if necessal NOV 1				- B	CMT-0069 APPLICANT(S)					84,983	
INFORMATION DISCLOSURE (Use several sheets if necessar)			sa NOV 162	008	Taehwan KWAK, et a	ıl.					
198			18	Æ)	FILING DATE 6-30-2006		GR	GROUP ART UNIT			
			RIDETAINS	DATENT	DOCUMENTS		-			11/4	
			U.S	PAIENI	DOCUMENTS		_				
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS	4	SUBCLASS		FILING DATE IF APPROPRIATE	
. 1											
•					-						
			T			†	T				
			 				+				
	_	,					+				
	- 1		U.S. PATEN	IT APPLIC	ATION PUBLICATIONS	L				L.,	
*EXAMINER		DOCUMENT NUMBER	DATE		NAME	CLASS	П	SUBC	ASS	FILING DAT	E RIATE
INITIAL	200	030114431	6-19-2003	GIROU/	ARD	514		182		8-26-2002	
		1									
			FORE	IGN PATE	ENT DOCUMENTS						
		DOCUMENT NUMBER	DATE		COUNTRY	CLASS		SUBC	LASS	TRANS YES	LATION NO
	102	20010019147	3-15-2001	KOREA	w/English Abstract						
	102	20040084482	10-6-2004	KOREA	w/English Abstract						
	102	20000027306	5-15-2000	KOREA	w/English Abstract						
									1		
		OTHER DOCUM		-	r, Title, Date, Pertinent						
		Stimulation of AMP-Ad Transport; Author: Ab	ctivated Protein K bud, et al.;Arch. l	inase (A.N Biochem.	APK) Is Associated with E Biophys.;vol. 380,pp. 347-2	nhancemer 352,2000	it of C	Glut 1-	Media	ted Gluco	se
		Regulation of muscle G 91, pp. 1073-1083, 2001	LUT-4 transcript	ion by A	AP-activated protein kinas	e; Author:	Zhen	g, et a	l.; J. A	ppl. Physic	ol.; vol.
EXAMINE	2	/Susan Hoffman/			DATE CONSIDERED	07/28/2	800				
		reference considered, wheth opy of this form with next co			mance with MPEP 609; Drav	v line throug	h citat	tion if	not in c	onformance	and not

FORM PTO-4820 (also form PTO-1449) ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. SHA

	ODMATION DISCLOSURE	CITATION	ATTY DOCKET NO. CMT-0069	· · · · · · · · ·	APPLICATION NO. 10/584,983			
INF	ORMATION DISCLOSURE (Use several sheets if necessary)		Taehwan KWAK, et a					
			FILING 6-30-2006		GROUP ART NYA			
		U.S. P	ATENT DOCUMENTS	•				
XAMINER IITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DAT		
IIIAL	1					II AITHOI	NATE.	
-							-	
۸ .								
						-		
						 	,	
		U.S. PATENT A	PPLICATION PUBLICATIONS	1	1	L		
XAMINER	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE		
IITIAL						IF APPROP	RIATE	
		FOREIGN	PATENT DOCUMENTS					
	DOCUMENT NUMBER DATE		COUNTRY	CLASS	SUBCLASS	TRANS	NO	
	OTHER DOCUMEN	ITS (Including A	Author, Title, Date, Pertinent	Pages, Etc.)	-		
	Coordinate Regulation of Carboxylase by AMP-act vol. 277,pp. 32571-32577.	Malonyl-CoA Deca vated Protein Kina 2002	arboxylase, sn-Glycerol-3-phospl se in Rat Tissues in Response to	nate Acyltran Exercise; Au	sferase, and A thor: Park, et a	cetyl0CoA l.; J. Biol. (Chem.;	
	Phosphorylation-activity Physiol.; vol. 92,pp. 2475	relationships of AN -2482,2002	IPK and acetyl-CoA carboxylase	in muscle; A	uthor: Park, e	t al.;J. App	l.	
KAMINER	/Susan Hoffman/		DATE CONSIDERED	07/28/200	18			
	itial if reference considered, whethe lude copy of this form with next com			line through o	citation if not in o	enformance	and not	

_									
				ATTY DOCKET NO. CMT-0069	ľ	APPLICATION NO. 10/584,983			
	INFORMATION DISCLOSURE		Taehwan KWAK, et al.						
				FILING 6-30-2006	1	GROUP ART	NYA		
		U.S	. PATENT	DOCUMENTS	<u></u>				
EXAMINER	DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DAT		
NITIAL		· ·					IF APPROP	COCIE	
							_		
				<u> </u>			_		
							_		
							-		
ı d		U.S. PATEN	T APPLIC	ATION PUBLICATIONS					
XAMINER NITIAL	DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
1									
		FORE	IGN PATE	NT DOCUMENTS		<u> </u>			
	DOCUMENT NUMBER	DOCUMENT NUMBER DATE		COUNTRY	CLASS	SUBCLASS	TRANS YES	LATION NO	
							120		
		1		Ę.					
				-				. "	
	OTHER DOCUME	NTS (Including	g Author	, Title, Date, Pertinent	Pages, Etc.)	l	1	
	Mechanism for Fatty A vol. 277, pp.3829-3835,2	cid "Sparing" Eff 2002	ect on Gl	ucose-induced Transcription	on; Author: I	Cawagachi, et a	l.; J. Biol.	Chem.;	
t	Inhibition of Inducible	Nitric-oxide Synth	ase by A	ctivators of AMP-activated	l Protein Kin	ase: Author: Pi	lon, et al.:	J. Biol.	
	Chem.; vol. 279,pp. 207	67-74, 2004		ctivators of AMP-activated			.,,		
XAMINE	R /Susan Hoffman/			DATE CONSIDERED	07/28/200	8			
XAMINE	ER: Initial if reference considered, wheth d. Include copy of this form with next co	er or not citation is	in conform	nance with MPEP 609; Draw	line through	citation if not in c	onformance	and not	

Form PTO-4820 (also form PTO-1449) ALL REFERENCES CONSIDERED EXCEPT WHERE LINES THROUGH. SHI

			ATTY DOCKET NO. CMT-006		APPLICATION NO.						
	INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				CMT-0069 10/584,983 Taehwan KWAK, et al.						
		(Ose several sneets il necess	ary)	FILING 6-30-2000	70	GROUP ART NYA					
			U.S.	PATENT DOCUMENTS							
INER		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE				
_							IF AFFROM	NOTE			
						1					
_					1						
			U.S. PATENT	APPLICATION PUBLICATIONS							
INER L		DOCUMENT NUMBER	DATE	. NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE				
	7							:			
								3.60			
			FOREIG	N PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO				
		A									
				Author, Title, Date, Pertiner				-			
		AMP Kinase and Malon discovery; vol. 3,pp. 340	yl-COA: Targets f -351, April 2004	or Therapy of the Metaolic Syn	drome; Author:	Ruderman, et	al.; Nature	drug			

PPARy coactivator-1a expression during thyroid hormone-and contractile activity-induced mitochondrial adaptations;
Author: Irrcher, et al;Am. J. Physiol. Cell Physiol.vol. 284, c1669-c1677, 2003

Author: HTener, et al., Alie 3. Filyshor. Cen Physhol, vol. 2005, C1007-C1077, 2005

/Susan Hoffman/

'EXAM

'EXAM

EXAMINER

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED

07/28/2008

					ATTY DOCKET NO. CMT-0069		APPLICATION NO. 10/584,983				
		NATION DISCLOSURE (Use several sheets if necess			Taehwan KWAK, et al.						
•					FILING 6-30-2006		GROUP ART NYA				
			U.S.	PATENT	DOCUMENTS						
XAMINER IITIAL		DOCUMENT NUMBER	DATE	NAME CLASS		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE			
							1				
							+				
							-				
			U.S. PATENT	APPLICA	ATION PUBLICATIONS			L			
KAMINER ITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE			
:			FOREIG	N PATE	NT DOCUMENTS						
		DOCUMENT NUMBER DATE			COUNTRY		SUBCLASS	TRANS	LATION NO		
									-		
						<u> </u>					
-											
		OTHER DOCUME		Author	, Title, Date, Pertinent i	Pages, Etc	l :.)	ı			
		AMP-activated protein 1 285-289, 1999	cinase phosphoryle	tion of e	ndothelial NO synthase; A	uthor: Che	n, et al.; FEBS I	etters 443,	pp.		
		Coordinated reduction of PGC1 AND NRF1, Auti	f genes of oxidativ	e metabo (AS ;vol.	olism in humans with insul 100, No. 14; pp. 8466-847	in resistance 1, 2003	e and diabetes:	Potential ro	le of		
•											
KAMINE	R	/Susan Hoffman/			DATE CONSIDERED	07/28/20	08				
		reference considered, whether			nance with MPEP 609; Draw	line through	citation if not in	conformance	and not		
nsidered	a. Include	copy of this form with next co	nmunication to app	iicant.							

FORM PTO-A820 (also form PTO-1449) ALL REFERENCES CONSIDERED EXCEPT WHITE LINES THROUGH. SHIP PAGE 1 THROUGH. SHIP PAGE 1 THROUGH.

Application Number ocket Number (Optional) 10/584,983 CMT-0069 INFORMATION DISCLOSURE CITATION Taehwan KWAK, et al. Group Art Unit (Use several sheets if necessary) Filing Date NYA 6-30-2006 llnhibitory Activity of Dincylglycerol Acyltransferase by Tanshinones from the Root Salvia miltiorrhiza; Author: Ko, et al.; Arch. Pharm. Res.; vol. 25.pp. 446-448, 2002 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) *EXAMINER INITIA Dihydrosotambinone I Protects Against Menadione-Induced Toxicity in a Primary Culture of Rat Hepatocytes; Author: 1p, et al., Planta Med.; 68,pp. 1077-1081, 2002 Aldose Reductase Inhibitory Constituents of the Root of Salvia miltiorhiza BUNGE; Author: Tezuka, et al.; Chem. Pharm. Bull., vol. 45, No. 8; pp. 1366-1311,1997 Poesible Aktive Components of Tan-Shen (Salvia militorrhiza) for Protection of the Myocardium Against Ischemia-Induced Derangements; Author: Yagi, et al.; Planta Med.; vol. 55; pp. 51-54, 1989 Role of UCP2 and UCP3 in Nutrition and Obesity; Author: Nagy, et al.; Nutrition; vol. 20, pp. 139-144,2004 Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia; Author: Marsin, et al.; Curr. Biol.; vol. 10,pp. 1247-1255, 2000 5-Aminomidazoie-4-Carboxamide Riboside Mimics the Effects of Insulin on the Expression of the 2 Key Gluconeogenic Genes PEPCK and Glucose-6-Phosphatase; Author: Lochead, et al.; Diabetes; vol. 49,pp. 896-903,2000 Mitochondrial fission in apoptosis, neurodegeneration and aging; Author: Bossy-Wetzel, et al.; Curr. Opin. Cell Biol.; vol. 15, pp.766-716, 2003 Mitochondrial Dysfunction in the Elderly: Possible Role in Insulin Resistance; Author: Peterson, et al.; Science; vol. 300, pp. 1140-1142, 2005 Decreased mitochondrial DNA content in peripheral blood precedes the developement of non-insulin-dependent diabetes mellitus; Author: LEE, et al.; Diabetes Res. Clin. Pract.; vol. 42,pp. 161-167, 1998 Mechanisms Controlling Mitochondrial Biogenesis and Respiration through the Thermogenic Conctivator PGC-1; Author: WU, et al.; Cell; vol. 98, pp. 115-124,1999 DATE CONSIDERED 07/28/2008

EXAMINER *EXAMINER: Initial if clintion considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include capy of this form with next communication to applicant.

Application Number set Number (Optional) 10/584,983 CMT-0069 INFORMATION DISCLOSURE CITATION Taehwan KWAK, et al. Group Art Unit (Use several sheets if necessary) Filing Date NYA 6-30-2006 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Effects of Tanshinone VI on the Hypertrophy of Cardiac Myocytes and Fibrosis of Cardiac Fibroblasts to Neonatal Rats; Author: Maki, et al.; Planta Med.; vol. 68, pp. 1103-1107,2002 *EXAMINER INITIAL Tanshinones inhibit mast cell degranulation by interfering with lgE receptor-mediated tyrosine phosphorylation of PLCgamma2 and MAPK; Author; Choi, et al.; Planta Med.; vol. 70,pp. 178-180, 2004 Novel Diterpenoid acetylcholinesterase Inhibitors from Salvia militorhiza; Author: Ren, et al.; Planta Med.;vol. 70, pp. 201-204, 2004 Sodium tanshinoon IIA sulfonate derived from Danshen (Salvia miltiorrhiza) attenuates hypertrophy induced by angintensin II in cultured neonatal rat cardiac cells; Author: Takahashi, et al.; Biochemical Pharmacology; vol. 64, pp. 745-759, 2002 Antibacterial Activities of Cryptotanshinonee and Dihydrotanshinone I from a Medicinal Herb, Salvia militorrhiza Bunge; Author: Lee, et al.; Biosci. Biotechnol. Biochem.; vol. 63(12), pp. 2236-2239,1999 Inhibition of interleukin-12 and interferon-y production in immune cells by tanshinones from Salvia miltiorrhiza; Author: Kang, et al.; Immunopharmacology; vol. 43, pp. 355-361,2000 Sodium tanshinone IIA sulfonate mediates electron transfer reaction in rat heart mitochondria; Author: Zhou, et al.; Biochemical Pharmacology; vol. 65, pp. 51-57, 2003 Tanshinon. (Salvia militiorrhzae Extract) Preparations Attentuate Aminoglycoside Induced Free Radical Formation In Viro and Ottotxicity In Vivo; Author; Wang, et al.; Antimicrobial Agent & Chemotherapy; vol. 47, No. 6; pp. 1836-1841, June 2043 INTERNATIONAL SEARCH REPORT; International Applicaton No. PCT/KR2004/003546; International Filing date: December 30, 2004; Date of Mailing March 11, 2005 (All references cited in Search Report are listed above) Written Opinion for Application No. PCT/KR2004/003546 dated December 30, 2004 International Preliminary Exam Report for Application No. PCT/KR2004/003546 dated December 30, 2004

EXAMINER /Susan Hoffman/ *EXAMINER: Initial if citation considered, whether or not citation is to conformance with MPEP Section 609; Draw line through citation if not to conformance and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED

07/28/2008